Tumor-Induced Osteomalacia Market Expected to Reach $153.00 Million by 2034, Growing at a CAGR of 2.6%

𝐓𝐡𝐞 𝐭𝐮𝐦𝐨𝐫-𝐢𝐧𝐝𝐮𝐜𝐞𝐝 𝐨𝐬𝐭𝐞𝐨𝐦𝐚𝐥𝐚𝐜𝐢𝐚 𝐦𝐚𝐫𝐤𝐞𝐭 𝐬𝐢𝐳𝐞 𝐰𝐚𝐬 𝐯𝐚𝐥𝐮𝐞𝐝 𝐚𝐭 𝐔𝐒𝐃 𝟏𝟏𝟖.𝟐𝟓 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟒 𝐚𝐧𝐝 𝐢𝐬 𝐞𝐱𝐩𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐢𝐬𝐞 𝐭𝐨 𝐔𝐒𝐃 𝟏𝟓𝟑.𝟎𝟎 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟒. 𝐓𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐬 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐞𝐱𝐡𝐢𝐛𝐢𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟐.𝟔% 𝐟𝐫𝐨𝐦 𝟐𝟎𝟐𝟓 𝐭𝐨 𝟐𝟎𝟑𝟒.

𝐕𝐚𝐫𝐢𝐨𝐮𝐬 𝐟𝐚𝐜𝐭𝐨𝐫𝐬 𝐩𝐫𝐨𝐩𝐞𝐥𝐥𝐢𝐧𝐠 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭 𝐝𝐞𝐦𝐚𝐧𝐝 𝐢𝐧𝐜𝐥𝐮𝐝𝐞:
• The tumor-induced osteomalacia market is growing due to the creation of innovative treatments, like fibroblast growth factor-23 (FGF23) inhibitors, and heightened research and development efforts for better therapeutic alternatives.
• The increasing emphasis on targeted therapies will be one of the key trends in the tumor-induced osteomalacia market.
• One of the major factors affecting the growth of the tumor-induced osteomalacia market is the increasing awareness, which is leading to timely and accurate diagnosis.

𝐆𝐞𝐭 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐚𝐠𝐞𝐬 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.polarismarketresearch.com/industry-analysis/tumor-induced-osteomalacia-market/request-for-sample

𝐖𝐡𝐚𝐭 𝐈𝐬 𝐓𝐮𝐦𝐨𝐫-𝐈𝐧𝐝𝐮𝐜𝐞𝐝 𝐎𝐬𝐭𝐞𝐨𝐦𝐚𝐥𝐚𝐜𝐢𝐚?
Abnormal vitamin D and phosphate metabolism result from a small tumor-secreting fibroblast growth factor 23 (FGF23), which causes tumor-induced osteomalacia (TIO), a rare endocrine disorder. An excess of FGF23 is secreted by phosphaturic mesenchymal tumors (PMTs), which are small, benign, or malignant tumors in the soft tissues or bones. Bone pain, fractures, muscle weakness, and exhaustion are among the symptoms. Children may experience skeletal abnormalities, growth retardation, and abnormalities in their gait. To maintain PTH within a normal range, treatment entails taking calcium and active vitamin D supplements.

𝐌𝐚𝐣𝐨𝐫 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬:
The existence of both big and small companies contributes to the extreme fragmentation of tumor-induced osteomalacia market. Among the leading market participants are:

• Ultragenyx Pharmaceutical Inc.
• Kyowa Kirin Co., Ltd.
• Eli Lilly and Company
• Amgen Inc.
• Novartis AG
• Sanofi S.A.
• Pfizer Inc.
• AbbVie Inc.
• Horizon Therapeutics

𝐁𝐮𝐲 𝐍𝐨𝐰 𝐓𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:
https://www.polarismarketresearch.com/buy/4198/2

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰:
• The tumor-induced osteomalacia market is segmented based on treatment type, end-users, and region.
• Based on treatment type, the market is segmented into surgery and drugs & supplements.
• Due to the growing use of pharmaceutical treatments such as phosphate supplements and fibroblast growth factor-23 (FGF23) inhibitors, such as burosumab, the drugs & supplements segment accounted for the largest market share.
• Due to the availability of advanced diagnostic and treatment facilities, such as imaging technologies and surgical procedures, the hospital segment had the largest market share.

By Treatment Type Outlook
• Drugs & Supplements
• Surgery

By End Users Outlook
• Hospitals
• Ambulatory Surgery Centers
• Speciality Clinics
• Others

𝐑𝐞𝐠𝐢𝐨𝐧𝐚𝐥 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞:
o North America (U.S., Canada)
o Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
o Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
o Latin America (Brazil, Mexico, Argentina)
o Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

𝐌𝐨𝐫𝐞 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐋𝐚𝐭𝐞𝐬𝐭 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:
Blood Transfusion Diagnostics Market
https://www.polarismarketresearch.com/industry-analysis/global-blood-transfusion-diagnostics-market

Transcatheter Aortic Valve Replacement (Tavr) Market
https://www.polarismarketresearch.com/industry-analysis/transcatheter-aortic-valve-replacement-tavr-market

Airway Management Devices Market
https://www.polarismarketresearch.com/industry-analysis/airway-management-devices-market

Alzheimer's Therapeutics Market
https://www.polarismarketresearch.com/industry-analysis/alzheimers-therapeutics-market

Cancer Pain Management Market
https://www.polarismarketresearch.com/industry-analysis/cancer-pain-management-market

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter

𝐀𝐛𝐨𝐮𝐭 𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 & 𝐂𝐨𝐧𝐬𝐮𝐥𝐭𝐢𝐧𝐠, 𝐈𝐧𝐜:

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

This release was published on openPR.